AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,332 | +37.9% | 27,600 | +27.8% | 0.00% | +50.0% |
| Q2 2023 | $966 | +19.0% | 21,600 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $812 | +8.7% | 21,600 | +54.3% | 0.00% | 0.0% |
| Q4 2022 | $747 | -99.8% | 14,000 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $417,000 | +111.7% | 14,000 | +3.7% | 0.00% | – |
| Q1 2022 | $197,000 | -24.5% | 13,500 | +9.8% | 0.00% | -100.0% |
| Q4 2021 | $261,000 | -1.9% | 12,300 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $266,000 | -12.8% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $305,000 | -9.8% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $338,000 | +12.3% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $301,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |